Texas MPN Workshop 2022 | An insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (MPN-U)
Claire Harrison
• 24 Aug 2022
Claire Harrison, MD, DM, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, shares some insights into the challenges of diagnosing and treating patients with myeloproliferative neoplasm-unclassifiable (MPN-U). Prof. Harrison also discusses some ongoing research being conducted in the UK evaluating this subset of MPN patients and future outlooks. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.
Disclosures
Research funding: Celgene, Constellation, Novartis Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra
